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Perivascular epithelioid cell tumor (PEComa) is an extremely rare neoplasm that appears to arise most commonly at
visceral (especially gastrointestinal and uterine), retroperitoneal, and abdominopelvic sites. Malignant PEComas exist
but are very rare. These tumors represent a family of mesenchymal neoplasms, mechanistically linked through
activation of the mTOR signaling pathway. Metastatic PEComa is a rare form of sarcoma for which no effective
therapy has been described previously and that has a uniformly fatal outcome. Although there is no known
effective therapy, the molecular pathophysiology of aberrant mTOR signaling provides a scientific rationale to target
this pathway therapeutically. The difficulty in determining optimal therapy, owing to the sparse literature available,
led us to present this case. On this basis, we report a case of metastatic retroperitoneal PEComa treated with an
oral mTOR inhibitor, with everolimus achieving significant clinical response.
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The PEComa family of tumors consists of related
mesenchymal neoplasms that exhibit myomelanocytic
differentiation and share a distinctive cell type, the peri-
vascular epithelioid cell, or PEC [1,2].
The major members of this family include lymphangio-
leiomyomatosis (LAM), a disease predominantly present-
ing as numerous nodular and interstitial pulmonary
lesions in premenopausal women; angiomyolipoma, com-
monly identified as an asymptomatic renal lesion with evi-
dence of vascular, muscular and adipocytic differentiation;
and PEComa, an epithelioid malignancy with clear-to-
granular eosinophilic cytoplasm typically arising in the
gastrointestinal tract, retroperitoneum, uterus or somatic
soft tissues, composed of nests and sheets of epithelioid or
occasionally spindled cells, intimately related to blood ves-
sel walls [3,4].
Tumors of the PEComa family are rare and usually
occur sporadically. LAM and angiomyolipoma also are
seen at high frequency in patients with tuberous* Correspondence: vmichalaki@usa.net
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reproduction in any medium, provided the orsclerosis complex (TSC), a disorder caused by mutation
of TSC1 or TSC2, for which the gene products nega-
tively regulate mTORC1 through inhibition of the
mTOR kinase activator, RHEB [5]. Both TSC1 and TSC2
gene products are involved in multiple cellular pathways,
including regulation of cell proliferation, migration and
differentiation through inhibition of the Rheb/mTOR/
p70S6 kinase-signaling pathway [6]. Inactivation of the
tuberin/hamartin complex in TSC thus leads to the acti-
vation of mTOR and the phosphorylation of p70S6K
and ribosomal protein S6, and further promotes transla-
tional initiation and cell growth. This mTOR pathway is
reported to be inappropriately up regulated not only in
TSC-associated AML, but also in sporadic angiomyoli-
poma or PEComas.
Most PEComas are benign tumors and do not recur
after complete surgical resection. However, a subset of
PEComas exhibits malignant behavior, with either locally
invasive recurrences or development of distant metas-
tases, most commonly in the lung. No effective therapy
for malignant PEComa has been described. Recently, Ita-
liano et al. described transient improvement in two
patients with malignant PEComa treated with temsiroli-
mus, an inhibitor of mTOR [7]. Additionally, Bissleral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Postoperative chest CT scan. A chest CT scan showing
diffuse, small, thin-walled cystic lesions in the parenchyma.
Figure 2 Postoperative abdomen scan before everolimus
treatment.
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the mTOR inhibitor sirolimus on renal angiomyolipoma
and on LAM associated with the TSC. Subependymal
giant cell astrocytoma (SEGA), another TSC associated
neoplasm, can also be successfully managed by mTOR
inhibition, and everolimus is already an FDA-approved
drug for non-resectable SEGAs [9].
Altogether, these findings support the inhibition of
mTOR as a rational therapeutic target in tumors occur-
ring in patients with TSC as well as PEComas. On this
basis, we report a case of metastatic retroperitoneal
PEComa treated with an oral mTOR inhibitor, everolimus.
Case presentation
A 63-year-old woman underwent resection of a retroperi-
toneal angiomyolipoma in 2009. A metastatic workup
including a thoracic, abdominal and pelvic computed
tomography (CT) 1 year later revealed retroperitoneal
recurrence, which was completely resected. The surgical
specimen was routinely processed for histology. The
tumor was composed predominantly of spindle-shaped
cells arranged in fascicles. These spindled cells, with eosi-
nophilic cytoplasm, resembled smooth muscle cells.
The comparison with the tumor resected in 2009
described as angiomyolipoma showed the same morphol-
ogy as the recurrent tumor. Immunohistochemistry
showed the neoplastic cells positive for HMB 45, Melan-
A, vimentin and CD 117 (focally). The neoplastic cells
were negative for SMA, Pan CK, CD 34 and S-100.The
pathological characteristics in combination with immuno-
phenotypes are consistent with the diagnosis of PEComa.
The patient had remained disease free for 4 months
when the follow-up CT scans revealed new lesions in the
lungs and recurrence in the abdomen (Figures 1 and 2).
Surgery was initially considered, but the curability was
estimated to be quite low considering the presence of
lung metastases. Based on the immunohistochemical
findings, which showed tumor cells positive for CD 117,
she was placed on targeted therapy with the tyrosine
kinase inhibitor imatinib mesylate. Treatment with ima-
tinib was stopped with evidence of disease progression
after 5 months. On the basis of published studies that
showed activation of the mTOR pathway in PEComas,
the institutional board approved everolimus as an off-
label treatment for this patient [10]. This treatment
option was discussed with the patient, who provided
informed consent for treatment with everolimus as well
as retrospective review of the medical records and eva-
luation of archival tumor specimens according to institu-
tional review board–approved protocols. Everolimus was
initiated at 10 mg per day. The dose was similar to the
approved dosage in renal cell cancer. The first tumor
evaluation carried out after 12 weeks revealed disappear-
ance of the lung lesions and a MRI of the abdomen thesame day revealed a significant response of the abdom-
inal mass (Figures 3 and 4). Everolimus treatment was
well tolerated, with grade 1 stomatitis and limited skin
toxicity. The patient has continued with this treatment on
an outpatient basis without signs of disease progression
over 10 months before evidence of new recurrence in the
retroperitoneum. She subsequently had an additional sur-
gical resection and remains alive with the disease
37 months after primary diagnosis.
Discussion
A subset of PEComas exhibits malignant behavior, with
either locally invasive recurrences or development of
distant metastases, most commonly in the lung. A chal-
lenge regarding these tumors is their management. Sur-
gery seems to be the only approach for aggressive cases,
Figure 3 Chest CT scan after treatment with everolimus.
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nificant results. However, this is based on few cases as
no therapeutic trial has so far been implemented. There
are obvious difficulties to performing a therapeutic trial
mainly because of the rarity of the disease. Recent stu-
dies demonstrated TSC1/2 inactivation and m-TOR
hyperactivation in non-TSC AMLs and in extrarenal
PEComas using immunohistochemistry and Western
blot analysis [11]. Based on the fact that PEComas share
activation of the mTOR pathway with LAM and angio-
myolipoma in many instances, we treated our patient
with everolimus, an inhibitor of mTOR. We have
observed significant clinical response with a near com-
plete response of greater than 10 months’ duration.
Our data are consistent with findings published to date
on the activity of mTOR inhibitors in tumors known to be
biologically related to PEComas, specifically angiomyoli-
poma and LAM. After case reports of patients withFigure 4 Abdominal scan after treatment with everolimus.renal angiomyolipoma and LAM responding to siroli-
mus were published, Bissler et al. [8] reported on the
treatment of 25 patients with angiomyolipoma or LAM
with sirolimus for 12 months followed by 12 months of
observation. After 12 months of therapy, the angiomyo-
lipoma volume decreased 53% but returned to 86% of
baseline after the year of observation, which indicated
the need for continued inhibition to maintain tumor
shrinkage. Less impressive improvements in respiratory
function were observed in patients with LAM, which
also reversed on observation alone. Interestingly, facial
angiofibromas associated with tuberous sclerosis also
have significantly improved with sirolimus therapy in a
case report [10].
Other evidence to support activation of the mTOR
pathway in PEComas has also recently been described.
Kenerson et al. reported immunohistochemical evidence
of mTORC1 activity in 15 PEComas and absence of
AKT phosphorylation in 14 tumors, which suggests the
loss of TSC1 or TSC2 as potential mechanisms [11].
Similarly, Pan et al. described elevated phospho-
p70S6K and reduced phospho-AKT in 11 of 12 PECo-
mas. Seven of these tumors had loss of heterozygosity of
the TSC2 region, and one additionally showed loss of
heterozygosity of TSC1 [12].
The efficacy of mTOR inhibitors has also been
explored in patients with a heterogeneous mix of other
metastatic sarcomas, in each case with only a modest
response rate. However, the status of mTOR activation
of these sarcomas is unknown, although in one study the
presence of S6 phosphorylation correlated with a higher
likelihood of disease control with an mTOR inhibitor
[9]. Taken together, these observations suggest that acti-
vation of mTOR through loss of the TSC1/TSC2 repres-
sor complex, or potentially by other means, is likely a
common and critically pathogenic event in PEComas.
Inhibition of mTOR has resulted in significant clinical
activity in patients with PEComa and merits additional
investigation in a prospective study. Absence of immuno-
histochemical evidence of TSC2 expression or the less
specific presence of S6 phosphorylation may be predictive
markers for responsiveness to inhibitors of mTORC1.
These findings additionally unify the concept of PEComa,
AML and LAM as closely related pathologic entities, from
histology to genetic changes, to demonstrate the therapeu-
tic benefit of mTOR blockade. Additionally, everolimus,
which could be orally administrated, may be more conve-
nient than infused drugs such as temsirolimus for both
patients and medical facilities.
Conclusion
Our report indicates that prolonged treatment of malig-
nant PEComas with everolimus may result in durable
tumor responses. Because of the very low frequency of
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cult to conduct clinical trials; therefore, as indicated by
our case and past reports, mTOR inhibitors may be one
of the best treatment options for this malignant disease.
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